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Highlights for Review 30 
 Metabolomic analysis of lamellar dialysate can differentiate horses developing experimental 31 
sepsis-associated laminitis from controls.  32 
 Malate, pyruvate, aconitate and glycolate in lamellar dialysate, and malate alone in plasma, 33 
were identified as the source of differentiation. 34 
 Changes in energy metabolism intermediates in the lamellar interstitium occurred during 35 
laminitis development and were not present in plasma. 36 
 Further investigation of local bioenergetic failure as a cause of laminitis due to sepsis is 37 
warranted. 38 
 Open profiling could further assess changes to the metabolome elicited by laminitis. 39 
Abstract 40 
Lamellar bioenergetic failure is thought to contribute to laminitis pathogenesis but 41 
current knowledge of lamellar bioenergetic physiology is limited. Metabolomic analysis (MA) 42 
can systematically profile multiple metabolites. Applied to lamellar microdialysis samples 43 
(dialysate), lamellar bioenergetic changes during laminitis (the laminitis metabolome) can be 44 
characterised. The objectives of this study were to develop a technique for targeted MA of 45 
lamellar and skin dialysate in normal horses, and to compare the lamellar and plasma 46 
metabolomic profiles of normal horses with those from horses developing experimentally 47 
induced laminitis. Archived lamellar and skin dialysate (n=7) and tissue (n=6) from normal 48 
horses, and lamellar dialysate and plasma from horses given either 10 g/kg oligofructose 49 
(treatment group, OFT; n=4) or sham (control group, CON; n=4) were analysed. The 50 
concentrations of 44 intermediates of central carbon metabolism (CCM) were determined 51 
using liquid chromatography – tandem mass spectrometry. Data were analysed using 52 
multivariate (MVA) and univariate (UVA) analysis methods. 53 
 54 
The plasma metabolome appeared to be more variable than the lamellar metabolome 55 
by MVA, driven by malate, pyruvate, aconitate and glycolate. In lamellar dialysate, these 56 
metabolites decreased in OFT horses at the later time points. Plasma malate was markedly 57 
increased after 6 h in OFT horses. Plasma malate concentrations between OFT and CON at 58 
this time point were significantly different by UVA. MA of lamellar CCM was capable of 59 
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differentiating horses developing experimental laminitis from controls. Lamellar malate, 60 
pyruvate, aconitate and glycolate, and plasma malate alone were identified as the source of 61 
differentiation between OFT and CON groups. These results highlighted clear discriminators 62 
between OFT and CON horses, suggesting that changes in energy metabolism occur locally in 63 
the lamellar tissue during laminitis development. The biological significance of these 64 
alterations requires further investigation. 65 
 66 
Keywords: Bioenergetic; Chromatography; Energy metabolism; Metabolomic; Sepsis.   67 
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Introduction 68 
Failure of lamellar energy metabolism (bioenergetic failure) is thought to be involved in 69 
the pathophysiology of sepsis-related (Belknap et al., 2009), endocrinopathic (French and 70 
Pollitt, 2004; Pass et al., 1998) and supporting limb (van Eps et al., 2010) laminitis in the 71 
horse. High lamellar glucose consumption has been demonstrated both in vitro (Pass et al., 72 
1998) and in vivo (Wattle and Pollitt, 2004). Lamellar hemidesmosomes, specialised 73 
multiprotein complexes that participate in the attachment of epithelial cells to their underlying 74 
basement membrane (Borradori and Sunnenberg, 1999), are lost in the absence of glucose and 75 
the dermo-epidermal attachment becomes weak (French and Pollitt, 2004; Pass et al., 1998). It 76 
has recently been proposed that sepsis-related laminitis may also occur secondary to 77 
inappropriate utilisation of energy substrates (i.e. glucose) (Belknap et al., 2009), as is thought 78 
to occur in sepsis-related organ dysfunction in humans (Callahan and Supinski, 2005; 79 
Fullerton and Singer, 2011; Leverve, 2007; Singer, 2008).  Despite the purported role of 80 
energy failure in laminitis pathogenesis, current knowledge about lamellar bioenergetic 81 
physiology is limited. 82 
 83 
The goal of metabolomic analysis (MA) is the comprehensive measurement of 84 
metabolite concentrations associated with a biological system at the cellular, tissue or whole 85 
organism level (Goodacre et al., 2004). MA results in the systematic profiling of multiple 86 
metabolites and their temporal (or population) changes in biofluids and tissues (Oliver et al., 87 
1998). It can be undertaken using two broadly different approaches, namely, open (or 88 
untargeted) profiling metabolomics or targeted (quantitative) metabolomics (Goodacre et al., 89 
2004). Targeted metabolomics in veterinary science can be regarded as an extension of a 90 
clinical chemistry panel whereby several predetermined analytes are quantitatively measured 91 
to assess their role in an underlying process. A recent open metabolomics study of serum from 92 
horses before and after experimentally-induced laminitis revealed evidence of dysregulation 93 
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of fatty acid metabolism, accumulation of organic acids (lactate) and identified that the amino 94 
acid citrulline decreased in serum prior to the onset of clinical laminitis (foot pain) (Steelman 95 
et al., 2014). 96 
 97 
Using tissue microdialysis, our laboratory has examined the major energy metabolites 98 
(glucose, lactate and pyruvate) in the interstitium of the lamellar and skin dermis in normal 99 
horses over 24 h (Medina-Torres et al., 2014).  In the current study we sought to combine 100 
tissue microdialysis and metabolomics to examine the changes in lamellar energy central 101 
carbon metabolism that occur locally during the development of laminitis. The analysis of the 102 
three major energy metabolites previously described (Medina-Torres et al., 2014) was 103 
considerably extended in this study by measuring the major energy metabolite pathway 104 
intermediates of glycolysis, the pentose phosphate pathway and the Krebs cycle, as well as 105 
nucleotides and co-factors. The primary aim of this MA was to determine the source and/or 106 
metabolic sequelae of any perturbation caused by experimental induction of laminitis and 107 
subsequent bioenergetic failure. Our objectives were: (1) to develop a reliable and 108 
reproducible technique for MA of equine lamellar and skin microdialysis samples (dialysates) 109 
and tissue samples using high performance liquid chromatography (HPLC) coupled to tandem 110 
mass spectrometry (MS/MS); (2) to compare dialysate and tissue extracts of lamellar tissue 111 
with the skin using targeted (quantitative) MA, and (3) to use targeted metabolomics to 112 
compare serial lamellar and plasma samples from normal horses with those of horses 113 
undergoing laminitis induction using the oligofructose (OF) model. 114 
 115 
Materials and methods 116 
Samples  117 
Archived (< 1 year at -80 °C) samples from adult Standardbred horses were used for 118 
analysis. Samples were collected during previous studies approved by The University of 119 
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Queensland Animal Ethics Committee (AEC) that monitors compliance with the Animal 120 
Welfare Act (2001) and the Code of Practice for the care and use of animals for scientific 121 
purposes (current edition) (approval numbers SVS/257/11/GJRF of 6October 2011 and 122 
SVS/338/11/UQ of 13 January 2012).  123 
 124 
Lamellar and skin microdialysis samples were obtained every 2 h over a 24 h study 125 
period from seven healthy horses; skin and lamellar tissue blocks were harvested from six 126 
healthy horses immediately after euthanasia, and lamellar microdialysis and plasma samples 127 
were obtained from eight horses at 0, 6, 12 and 24 h after nasogastric administration of either 128 
a bolus dose of 10 g/kg OF (Invita) (treatment group, OFT; n=4) as previously described (van 129 
Eps and Pollitt, 2006), or sham treatment (control group, CON; n=4).  130 
 131 
The OFT horses had developed Obel grade 1 lameness (Obel, 1948) at 18 - 22 h after 132 
OF dosing and had histological evidence of acute laminitis at 48 h. Dialysate was collected 133 
with coaxial microdialysis probes with a 0.5  10 mm, 100 kDa cut-off membrane (CMA20, 134 
CMA-Microdialysis), inserted into the lamellar tissue of one forelimb and into the skin dermis 135 
at the tail base as previously described (Medina-Torres et al., 2014). All probes were perfused 136 
with isotonic, polyionic sterile perfusion fluid (T1, CMA-Microdialysis) containing 40 g/L 137 
dextran-70 (Sigma-Aldrich) to prevent perfusate loss (Rosdahl et al., 1997). Plasma was 138 
separated by immediate centrifugation (15,000 × g, 10 min) of whole blood samples collected 139 
into heparinised tubes (Vacuette, Greiner Bio-One) in OFT and CON horses via a 16G 140 
indwelling catheter (Mila International) placed aseptically in the right jugular vein. 141 
 142 
Development and optimization of LC-MS/MS 143 
In each sample, central carbon metabolism (CCM) was assessed by liquid 144 
chromatography - tandem mass spectrometry (LC-MS/MS) using a targeted method. For 145 
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lamellar and skin microdialysis samples, assessment of the perfusion fluid (perfusate) was 146 
performed to determine its suitability as a calibration matrix. The performance of a perfusate-147 
based calibration was then measured and compared against an aqueous ‘blank’ calibration 148 
through standard addition of the metabolite panel (reference standards; Sigma-Aldrich) to the 149 
perfusate matrix. Thereafter lamellar and skin microdialysis samples were measured to assess 150 
the need for further optimization based upon sample-related effects on the analytical system. 151 
 152 
To analyse the metabolite composition of lamellar and skin dermis tissue sections, 153 
metabolites were extracted using a procedure adapted from Want et al. (2013). In brief, 50 mg 154 
of each sample were sliced with a scalpel, suspended in 2 mL of 1:1 methanol:purified water 155 
plus 2 µL 1 mM azidothymidine (AZT) as an internal quantitative standard, and homogenised 156 
for 5 min at 20,000 rpm using an Omni TH Homogenizer (Omni International). Purified water 157 
was generated using a water purification unit (Elga Purelab Classic; Veolia Water Solutions 158 
and Technologies). The fluid fraction/supernatant was collected and centrifuged for 15 min at 159 
13,000 g at 4 °C. The supernatant (800 µL) was retrieved and chloroform (800 µL) added 160 
before vortexing for 15 s. Samples were then centrifuged for 10 min at 13,000 g at 4 °C and 161 
the supernatant (upper polar phase; 600 µL) collected. Addition of chloroform (600 µL), 162 
vortexing and centrifugation were repeated. The upper polar phase was collected and dried 163 
down in a vacuum centrifuge (Eppendorf Concentrator Plus) for 180 min at 45 °C using the 164 
V-AQ program. The dried sample was resuspended immediately in 100 µL of purified water 165 
for LC/MS-MS analysis. Plasma (50 μL) was processed using the same extraction procedures, 166 
without the need for the initial tissue homogenization step. 167 
 168 
LC-MS/MS data were acquired using a Dionex UltiMate 3000 LC system coupled to an 169 
ABSciex 4000 QTRAP mass spectrometer as described by Dietmair et al. (2012), with the 170 
following modifications: the analytical column was equipped with a pre-column Security 171 
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Guard Gemini-NX C18 4 × 2 mm I.D. cartridge (Phenomenex) and five additional analytes 172 
were quantified, as well as AZT (internal standard). The LC system was controlled by 173 
Chromeleon software v6.80
n, and chromatographic separation achieved by injecting 10 μL 174 
onto a Gemini-NX C18 150 × 2 mm I.D., 3 μm 110 Å particle column (Phenomenex). The 175 
column oven temperature was controlled and maintained at 55 °C throughout the acquisition 176 
and the mobile phases (adapted from Luo et al., 2007), were as follows: 7.5 mM aqueous 177 
tributylamine (puriss plus grade; Sigma-Aldrich) adjusted to pH 4.95 (±0.05) with glacial AR-178 
grade acetic acid (eluent A; Labscan) and LC-grade acetonitrile (eluent B; Labscan). The 179 
mobile phase flow rate was maintained at 300 μL/min throughout the gradient profile (Table 180 
1), and introduced directly into the MS with no split.  181 
 182 
The MS was equipped with a TurboV electrospray source operated in negative 183 
ionisation mode, and data acquisition controlled by Analyst v1.5.2 software (ABSciex). The 184 
following optimised parameters were used to acquire scheduled Multiple Reaction Monitoring 185 
(sMRM) data: ion spray voltage −4500V, nebulizer (GS1), auxiliary (GS2), curtain (CUR) 186 
and collision (CAD) gases were 60, 60, 20 and medium (arbitrary units), respectively, 187 
generated in a N300DR nitrogen generator (Peak Scientific). The auxiliary gas temperature 188 
was maintained at 350 °C.  189 
 190 
A total of 44 analytes were quantified using HPLC-MS/MS; the analytes and analyte-191 
dependent parameters for the detection of central carbon metabolites are presented in 192 
Supplementary Table 1. For all analytes the entrance potential (EP) was -10 volts. Samples 193 
were run with sample- and analyte-relevant calibration standards and pooled quality control 194 
samples (Hodson et al., 2009; Sangster et al., 2006) to control for reproducibility of data 195 
acquisition and to ensure data integrity. The order of acquisition of the samples was 196 
randomised to remove/minimise any bias or batch effects related to sample type or, if 197 
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applicable, treatment regimes. Analyte stock solutions were prepared in purified water, and 198 
aliquots of each solution were mixed to achieve a final calibrant solution at 200 μM. This 199 
calibrant solution was diluted to provide a total of 20 calibration standards at 200, 150, 100, 200 
90, 70, 50, 40, 25, 12.5 and 1:1 serial dilutions to 0.006 μM, constituting 7 ≤ x ≤ 20 201 
calibration points for all analytes to account for differential responses in the mass 202 
spectrometer. 203 
 204 
Data processing and statistical analysis 205 
Data acquired by HPLC-MS/MS were processed using MultiQuant v2.1.1 software 206 
(ABSciex). Multivariate analysis (MVA) of the data was performed using SIMCA v13.0.3.0 207 
software (MKS Umetrics). Two MVA methods were applied, namely principal component 208 
analysis (PCA) and orthogonal projection to latent structures-discriminant analysis (OPLS-209 
DA). For more information relating to these methods see Trygg et al. (2007) and Bylesjö et al. 210 
(2006). 211 
 212 
In normal horses, results were compared between lamellar and skin dermis dialysate, 213 
and between lamellar dialysate samples and tissue sections. In the OF study animals, results 214 
were compared between lamellar dialysate from OFT and CON groups, between time points 215 
within each sample group, and between lamellar dialysate and plasma. Using GraphPad Prism 216 
v6.00 for Windows, univariate analysis (UVA) was then performed on selected metabolites 217 
identified by MVA. The data were tested for normality using D’Agostino-Pearson omnibus 218 
K2 normality tests; non-parametric tests were applied if the data failed this test. Metabolite 219 
concentrations in lamellar dialysate and plasma were compared at each time point between 220 
OFT vs. CON horses. Significance was set at P < 0.05. 221 
 222 
Results 223 
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There was no evidence to suggest that, in comparison to a water-based calibration, the 224 
T1 solution with 40 g/L dextran-70 matrix caused any overt suppression or enhancement of 225 
the MS detection of analytes from CCM. Lamellar and skin microdialysis samples were 226 
subsequently measured successfully after extraction, so no further processing of the samples 227 
was required. The metabolite composition of both lamellar and skin tissue sections was also 228 
successfully determined; without extensive testing of multiple methods the extraction protocol 229 
was deemed suitable for characterisation of intracellular CCM analytes in these two tissues. 230 
 231 
Skin vs. lamellar dialysate 232 
Multivariate analysis was used to compare the data obtained from lamellar and skin 233 
dialysate, initially using PCA to summarise the major sources of variance in the data. Fig. 1a 234 
shows the PCA scores plot for this comparison and it is clear from this plot that the 235 
distributions of the samples from the skin and the lamellae were similar and approximately 236 
overlap each other. When applying alternative colouring to the PCA (Fig. 1b) based upon 237 
horse (subject), some structure to the variance can be observed relating to the horse from 238 
which the samples were taken. Supervision of the MVA using OPLS-DA was also unable to 239 
clearly separate skin and lamellar samples based upon their detectable metabolome in this 240 
experiment (Fig. 1c). 241 
 242 
Lamellar dialysate vs. plasma 243 
PCA of the metabolome of these samples showed clear differences, as observed in Fig. 244 
2a. In general the plasma metabolome appeared more variable than that of the dialysate. This 245 
was driven by central carbon metabolites such as malate, where clear differences were not 246 
only observed between plasma and lamellar dialysate but also between the control and treated 247 
groups. Marked increases in malate where seen, particularly at the 6 h time point in the 248 
plasma of OFT-treated subjects (Fig. 2c). Fig. 2b shows the loadings relating to the scores 249 
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plot in Fig. 2a and highlights the variables and therefore the metabolites that are influential in 250 
the differentiation between plasma and lamellar dialysate. Clearly observable group- and 251 
time-dependent metabolite profile differences were also noted for metabolic intermediates 252 
such as aconitate (Fig. 2d), pyruvate (Fig. 2e) and glycolate (Fig. 2f). 253 
 254 
UVA of the lamellar dialysate revealed significantly (P<0.05) higher malate at the 6 h 255 
time point and lower malate and aconitate at the 24 h time point in OFT horses compared with 256 
CON (Appendix: Supplementary Fig. 1). Pyruvate and glycolate concentrations were not 257 
found to be significantly different between OFT and CON, however a decrease in the 258 
concentrations of all four metabolites was apparent in the OFT group at the later time points, 259 
while concentrations remained stable in the CON group (Appendix: Supplementary Fig. 1). 260 
Plasma malate concentrations increased significantly at the 6 h time point in OFT compared 261 
to CON horses (Appendix: Supplementary Fig. 2). 262 
 263 
OFT vs. CON 264 
After investigating the overall differences between metabolite concentrations in lamellar 265 
and plasma samples, a more directed analysis was performed to look specifically at the 266 
comparison between lamellar microdialysate samples from CON and OFT subjects, as well as 267 
comparing the same for plasma extracts. In the case of plasma extract samples, PCA and 268 
OPLS-DA models highlighted malate as the only major difference between the metabolome 269 
of the CON and OFT horses in plasma. In the case of the lamellar dialysate, models were 270 
generated for all time points other than the zero time point (i.e. before treatment) and 271 
therefore metabolomic differences were observed based upon OF treatment (Figs. 3 a-f).  272 
 273 
Lamellar tissue extracts vs. skin tissue extracts 274 
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A comparison of tissue extracts from lamellae and skin was also performed in an 275 
attempt to assess the central carbon metabolomic differences between these tissues. Figs. 4a-f 276 
show the supervised (OPLS-DA) separation of the two tissue extracts and highlights a number 277 
of clear differences in the central carbon metabolite content of these tissues. It should be 278 
noted that the extraction procedure was controlled with a generalised internal standard (AZT) 279 
to account for losses/reduced recovery, and that the differences observed are not due to a 280 
consistent increase of metabolites in one tissue after extraction, since metabolite levels are 281 
both higher and lower in one tissue compared to the other. The lamellar extracts were found to 282 
be more variable in metabolite content than the skin extracts, as can be observed by the tighter 283 
distribution of the skin samples in the scores plot (Fig. 4a). 284 
 285 
Lamellar tissue extracts vs. lamellar dialysate 286 
 The central carbon metabolome of lamellar tissue extracts was compared with that of 287 
the lamellar dialysate to ascertain how well the microdialysate metabolite profile reflects the 288 
lamellar tissue. Figs. 5a and b show the loadings from unsupervised (PCA) and supervised 289 
(OPLS-DA) analyses of the samples (n=6/group), with a separation in Fig. 5a clearly resolved 290 
by supervision in Fig. 5b. Column plots of four metabolites are shown in Figs. 5c-f to 291 
highlight the differences in profile for many of the metabolites, the vast majority of which 292 
have much greater concentration in lamellar tissue with the exception of malate (Fig. 5f), 293 
succinate and glucose 1-phosphate. A summary of the concentrations of all analytes for the 294 
various biofluid and tissue extracts are detailed in the Appendix at Supplementary Table 2. 295 
 296 
Discussion 297 
A method for MA of equine lamellar and skin dialysate and tissue extracts was 298 
successfully developed and enabled measurement of the CCM in microdialysate, plasma and 299 
tissue extract samples. 300 
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 301 
Principal component analysis of the data from the lamellar and skin tissue of healthy 302 
adult horses demonstrated that, by comparison, lamellar and skin dialysate had a similar 303 
metabolite composition (Fig. 1a). When the PCA was coloured by subject (Fig. 1b) a pattern 304 
of variance related to the sample source (i.e. the horse) was observed. In general this means 305 
that the site of sampling (skin vs. lamellae) was not a major discriminating factor when 306 
considering possible differences in metabolome, whereas inter-subject variability showed a 307 
degree of influence on the metabolomic content of the tissues. Furthermore, OPLS-DA 308 
supervision of the MVA also failed to separate lamellar and skin dialysate samples based 309 
upon their CCM (Fig. 1c), meaning there was a degree of similarity in the metabolomic 310 
content of microdialysis samples obtained from these two collection sites. As the dialysate 311 
from both sites can be expected to contain metabolites that diffuse freely across the 312 
membrane, the similarities in dialysate composition demonstrates that in the normal (healthy) 313 
horse the interstitial fluid composition of the lamellar tissue is similar to that of the skin. 314 
 315 
Clear differences between the metabolome of lamellar dialysate and plasma from CON 316 
and OFT subjects were observed with PCA (Fig. 2a). Unexpectedly, the metabolome of the 317 
plasma samples was found to be more variable than that of the lamellar dialysate. This finding 318 
may seem surprising given the homeostatic control of plasma metabolite concentrations in 319 
particular but could possibly be explained by two factors; firstly the plasma sample is a 320 
snapshot in time whereas the microdialysate sample is collected over a longer period and as 321 
such provides a more ‘averaged signal’ of metabolite concentrations; secondly, and linked to 322 
the first, the plasma sample is more likely to be affected by external influences such as 323 
feeding immediately prior to sample collection.  324 
 325 
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The variability in plasma was driven by four central carbon metabolites (i.e. malate, 326 
aconitate, pyruvate and glycolate; Figs. 2b-f), which were not only influential in the 327 
differentiation between the two tissue sample types, but also provided differentiation between 328 
the CON and OFT groups (e.g. significant increase in malate at the 6 h time point in OFT 329 
plasma). However, when looking specifically at the comparison between plasma extracts from 330 
CON and OFT subjects in isolation, only malate was indicated as a discriminatory metabolite. 331 
The time-related profile for malate suggests that the determination of plasma concentrations 332 
for this metabolite may be a suitable early predictor of laminitis development (at least in 333 
laminitis due to alimentary oligofructose overload), although further investigations with larger 334 
subject numbers would be required to confirm its utility. Furthermore, determination of 335 
plasma malate concentrations at intermediate time points (e.g. hourly sampling from 0 – 12 h 336 
after OF administration) would be necessary to identify the evolution of this rise in malate, 337 
the time point when the maximum concentration (peak) is reached, and its duration (i.e. the 338 
potential diagnostic window). However, as malate is an intermediate metabolite with 339 
important roles in energy producing pathways such as the tricarboxylic acid cycle (TCA) in 340 
animals (Alberts et al., 2008) as well as the glyoxylate cycle in bacteria (Kornberg and Krebs, 341 
1957), and the naturally occurring malate molecule (i.e. L-malate) is identical in bacteria and 342 
mammals (Alberts et al., 2008), the source of plasma malate in the present study cannot be 343 
determined. It could be a by-product of bacterial fermentation of OF in the gastrointestinal 344 
tract, which would be consistent with the timing of the increase in plasma in this experiment. 345 
If this is the case, the use of malate as a predictor of laminitis in naturally occurring laminitis 346 
might be precluded.  347 
 348 
Contrary to malate, two different isoforms of lactate occur naturally: L-lactate in 349 
mammals and D-lactate in bacteria (Alberts et al., 2008). Thus, determining the plasma D-350 
lactate concentration could help establish if this and other intermediate metabolites (such as 351 
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malate) originated in the intestinal lumen as a result of the bacterial disbiosis known to occur 352 
after OF administration (Millinovich et al., 2006). However, the LC-MS/MS method used in 353 
this study could not distinguish between the two lactate isoforms, and other means of 354 
differentiation were not attempted. Furthermore, plasma lactate was not a discriminatory 355 
metabolite between the CON and OFT groups. Though the absence of a discriminatory shift 356 
in plasma lactate concentrations might indicate that the source of other measured metabolites 357 
(including malate) may be other than the intestinal intraluminal bacteria, this cannot be 358 
established with our findings in the present study.  359 
 360 
Thus, whether the discrimination between the CON and OFT groups observed with 361 
malate is attributable to an influx of bacterial metabolites from the intestine or a consequence 362 
of metabolic disruption attributable to the development of sepsis-associated laminitis in the 363 
horse remains to be determined. This could be an important future step in understanding the 364 
pathophysiology of sepsis-associated laminitis and in the identification of potential 365 
biomarkers for early disease diagnosis. 366 
 367 
MA of lamellar dialysate was capable of differentiating between OFT and CON groups. 368 
The analysis highlighted two metabolites (malate and aconitate) as clear discriminators 369 
between OFT and CON horses. These results suggest that changes in energy metabolism do 370 
occur locally in the lamellar tissue during laminitis development and warrant further 371 
investigation using the lamellar microdialysis technique. However, the changes may not be 372 
biologically significant as they occurred in the later time points, coinciding with the onset of 373 
lameness (18–22 h), and after the developmental phase of the disease. This is further 374 
confounded by the fact that microdialysis is an interstitial sample, where the observed 375 
changes may not represent the true intracellular metabolic status and could be affected by 376 
other processes such as inflammation. 377 
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 378 
In general, lamellar tissue was found to have higher metabolite concentrations in 379 
comparison to lamellar dialysate, with the exception of malate, succinate and glucose 1-380 
phosphate. The extracellular origin of the dialysate dictates that concentrations are likely to be 381 
lower than the intracellular pools, as the content of the dialysate consists for the most part of 382 
TCA intermediates and pyruvate, all of which are produced in the cellular cytoplasm. 383 
Assessing a more comprehensive dialysate metabolome using a larger microdialysis probe 384 
pore size and with the inclusion of amino acids, fatty acids and carbohydrates would be 385 
recommended for future studies in order to comprehensively examine lamellar metabolism 386 
during laminitis development. A similar approach was utilised recently for trapezius myalgia 387 
in humans (Hadrevi et al., 2013). Furthermore, concurrent assessment of regulatory enzymes 388 
of energy metabolism (glycolytic and oxidative) could help determine if lamellar energy 389 
failure is a feature of laminitis in the horse. Phosphofructokinase, a rate limiting enzyme of 390 
the glycolytic pathway, as well as electron transport chain components were genetically 391 
downregulated in muscle from a rodent sepsis model (Callahan and Supinski, 2005). 392 
 393 
The main limitations of our study were the low number of subjects included and that 394 
only 4/13 time points collected were assessed in OFT and CON horses (due to financial and 395 
logistical restrictions). However, despite these limitations, targeted MA and MVA were 396 
successful in differentiating OFT and CON horses and potential plasma/lamellar dialysate 397 
biomarkers were identified. 398 
 399 
Conclusions 400 
MA of the lamellar dialysate samples for central carbon metabolites was found to be 401 
capable of differentiating horses developing experimental sepsis-associated laminitis from 402 
controls in the OF model. Malate, pyruvate, aconitate and glycolate in lamellar dialysate, and 403 
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malate alone in plasma, were identified as the source of differentiation between OFT and 404 
CON groups. The origin and clinical usefulness of these potential biomarkers for early 405 
identification of naturally occurring laminitis remain to be determined. These significant 406 
changes in energy metabolism intermediates in the lamellar interstitium occurred during 407 
laminitis development and were not present in plasma samples, suggesting that further 408 
investigation of local bioenergetic failure as a cause of laminitis due to sepsis is warranted. 409 
Having established the central carbon metabolome in these samples the next step would most 410 
likely be an open profiling approach to further assess the changes to the metabolome elicited 411 
by experimentally-induced laminitis. 412 
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Figure Legends: 526 
 527 
Figure 1: MVA of skin and lamellar dialysate samples: (a) PCA scores plot of skin (S - blue) 528 
and lamellar (L - green) microdialysate showing similar data distributions for each tissue 529 
type. Numbers represent time points of collection; (b) PCA scores plot coloured by horse to 530 
show that some of the variance explained by the MV model is due to inter-subject (horse) 531 
variability; (c) OPLS-DA scores plot to show incomplete supervised separation between the 532 
sample metabolomes; (d) bar charts showing selected metabolites fumarate, glycolate, 533 
glyoxylate and α-ketoglutarate as an example of similar distributions in skin and lamellar 534 
microdialysate. 535 
 536 
Figure 2: MVA of lamellar dialysate and plasma samples: (a) PCA scores plot of lamellar 537 
dialysate (D - green) and plasma (P – blue) showing different data distributions for each 538 
tissue type. Letters next to each point represent the subject from which the sample was 539 
collected (A-D = oligofructose-treated horses; E-H = controls); (b) loadings plot for (a), 540 
highlighting the four variables (red points = metabolites; MAL: malate; PYR: pyruvate; 541 
ACO: aconitate; Glycol: glycolate shown in c-f) that were influential in the differentiation 542 
between the two tissue sample types. Profiles for (c) malate, (d) aconitate, (e) pyruvate, and 543 
(f) glycolate for each horse (X-axis: A – H) at each successive time point (0, 6, 12, 24 h = 544 
respectively, green and blue bars from left to right for each horse). 545 
 546 
Figure 3: Differences in the lamellar dialysate metabolome after oligofructose treatment; 547 
OFT – red, CON – green; (a) PCA at the 6 h time point; (b) profile of malate at the 6 h time 548 
point; (c) PCA at the 12 h time point; (d) profile of pyruvate at the 12 h time point; (e) PCA 549 
at the 24 h time point; (f) profile of aconitate at the 24 h time point. 550 
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 551 
Figure 4: Differences in the metabolome of lamellar extracts (green) and skin extracts (blue); 552 
(a) OPLS-DA scores plot of the extracts; (b) loadings plot of the metabolites with 4 553 
highlighted variables (metabolites) in red, each shown in detail in c-f as column plots of (c) 554 
citrate; (d) glycolate; (e) UDP-glucose and (f) dihydroxyacetone phosphate. The four 555 
highlighted metabolites show a clear difference in central carbon metabolite content, which 556 
results in separation of the two tissue extracts. 557 
 558 
Figure 5: Differences in the metabolome of lamellar dialysate (green) and lamellar tissue 559 
extracts (blue); (a) PCA scores plot of the comparison of lamellar dialysate vs. tissue extract; 560 
(b) OPLS-DA scores plot of lamellar dialysate vs. tissue extract; c-f column plots of (c) a-561 
ketoglutarate; (d) aconitate; (e) dihydroxyacetone phosphate and (f) malate. 562 
 563 
Table 1: Liquid chromatography mobile phase gradient profile. 564 
Time (min) Eluent A (%) 
0 100 
8 100 
20 80 
30 73 
31 0 
33 0 
34 100 
50 100 
 565 
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